About The Valsartan Lawsuits
People across the nation are joining class action lawsuits—and filing individual complaints—after taking valsartan-containing drugs contaminated with potentially carcinogenic (cancer-causing) chemicals.
Valsartan is a generic drug that, for years, was regarded as a safe and effective treatment for high blood pressure, kidney disease, and heart failure. However, a flawed manufacturing process led to hundreds of batches of the medication being contaminated with N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA), probable human carcinogens.
Though the catastrophic error was discovered and the drugs were recalled in 2018, the process causing the contamination had been used since around 2012—meaning countless patients were exposed prior to the recall.
If you or a loved one took a valsartan-containing medication between 2012 and 2018 and developed cancer or another serious illness, you may be eligible to take legal action. Those who took the drug but do not have cancer may still qualify to join a class action lawsuit. Read on to learn more.
What Is Valsartan?
Valsartan is an active ingredient used in many prescription drugs. It is classified as an Angiotensin II Receptor Blocker (ARB) and is intended to treat high blood pressure (hypertension) and heart failure. Patients may be prescribed the drug to improve survival following a heart attack, and it may also be used to protect the kidneys in certain patients.
Brand-name drugs containing valsartan include:
- Byvalson
- Diovan (single-ingredient)
- Diovan HCT
- Entresto
- Exforge
- Exforge HCT
- Prexxartan (single-ingredient)
- Valturna
- Vyduo
Many generic drugs also contain valsartan, including ones that were recalled for NDMA and NDEA contamination:
- Amlodipine and valsartan
- Amlodipine, valsartan and hydrochlorothiazide (HCTZ)
- Valsartan and hydrochlorothiazide (HCTZ)
- Valsartan
Why Is Valsartan Dangerous?
Though, like any drug, valsartan can cause side effects, the medication itself isn’t known to pose a cancer risk. Instead, the dangers arose from a faulty manufacturing process employed by China-based manufacturer Zhejiang Huahai Pharmaceutical, a company named in the lawsuits.
Around 2012, Zhejiang Huahai Pharmaceutical began producing valsartan using a sodium-azide-based synthesis to cut costs and improve manufacturing efficiency. Disturbingly, this method resulted in chemical reactions that formed probable carcinogens NDMA and NDEA.
In a display of true negligence, Zhejiang Huahai Pharmaceutical did not discover the contamination until mid-2018, when a routine quality test revealed the presence of NDMA (further tests also detected NDEA). They reported their findings to regulatory agencies like the FDA, resulting in the agency’s widespread recalls of valsartan-containing drugs beginning later that year.
Sadly, by that point, numerous contaminated batches of valsartan had already been distributed to and consumed by unknowing patients—likely for years.
Though each contaminated dose contained only small amounts of NDMA or NDEA, the risk to patients is still great since valsartan is frequently used in maintenance drugs intended to be taken routinely (often every day). This means that patients who took contaminated valsartan over an extended period may have been exposed to hazardous levels of carcinogens, increasing their cancer risk—and, in some cases, even causing them to develop cancer.
Add Comment